Wilmer Cutler Pickering Hale and Dorr represented Nuvalent, Inc. in the offering, and Simpson Thacher & Bartlett represented the underwriters. Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage...
Nuvalent’s $575 Million Common Stock Offering
MicroStrategy Incorporated’s $1.01 Billion Convertible Senior Notes Offering
Wilmer Cutler Pickering Hale and Dorr advised MicroStrategy Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the several initial purchasers. MicroStrategy...
MicroStrategy Incorporated’s $800 Million Convertible Senior Notes Offering
Wilmer Cutler Pickering Hale and Dorr represented MicroStrategy Incorporated in the offering. MicroStrategy® Incorporated (Nasdaq: MSTR) (“MicroStrategy”) announced that it has completed its offering of 2.25%...
MicroStrategy’s $800 Million Convertible Senior Notes Offering
Wilmer Cutler Pickering Hale and Dorr represented MicroStrategy® Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the initial purchasers. MicroStrategy Incorporated...
Astria Therapeutics’ $125 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Astria Therapeutics, Inc., and Cooley advised the underwriters. Astria Therapeutics, Inc. (Astria) (Nasdaq: ATXS) announced it completed its underwritten registered...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
PerkinElmer’s $5.25 Billion Acquisition of BioLegend
Wilmer Cutler Pickering Hale and Dorr advised PerkinElmer on the deal while Pillsbury Winthrop Shaw Pittman represented BioLegend. PerkinElmer, a global leader committed to innovating for...